MITOMICINA C NEL TRATTAMENTO DEI SARCOMI DEI TESSUTI MOLLI DELL'ADULTO IN FASE AVANZATA

Translated title of the contribution: Mitomycin C in treatment of advanced soft-tissue sarcomata in adults

L. Di Lauro, A. Balice, P. Papaldo, M. Lopez

Research output: Contribution to journalArticlepeer-review

Abstract

Mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks was administered to 15 evaluable patients with measurable advanced soft tissue sarcomas resistant to standard treatment. No response was observed. Disease stabilization occurred in 5 patients, with a median duration of 4 months. Toxicity was generally mild to moderate. On the basis of this study, mitomycin C, in the dosage and schedule used in the above study, cannot be recommended in the treatment of this disease.

Translated title of the contributionMitomycin C in treatment of advanced soft-tissue sarcomata in adults
Original languageItalian
Pages (from-to)83-85
Number of pages3
JournalClinica Terapeutica
Volume115
Issue number2
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Mitomycin C in treatment of advanced soft-tissue sarcomata in adults'. Together they form a unique fingerprint.

Cite this